Editas Medicine, Inc.

Massachusetts Institute of Technology

Duke University

Boston University

Ari E Friedland

Barrett Ethan Steinberg

Hariharan Jayaram

David A Bumcrot

Penrose O'Donnell

Morgan Lee Maeder

G Grant Welstead

James Joseph Collins

Timothy Kuan-Ta Lu

Hideki Kobayashi

Bryan R Cullen

Deepak Reyon

Mads Kearn

Michihiro Araki

Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.

Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA

CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.

CRISPR/CAS-related methods and compositions for treating herpes simplex virus

Genome editing systems and genetic constructs that target a herpes simplex virus (HSV) viral gene, where the systems comprise one Cas9 molecule, and a gRNA molecule, compositions and cells comprising such genome editing systems and genetic constructs as well as methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering, and for preventing, treating or reducing HSV infection.

CRISPR/cas-related methods and compositions for treating herpes simplex virus

CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.

CRISPR/CAS-related methods and compositions for treating sickle cell disease

Disclosed herein are genome editing systems and compositions that target a cystic fibrosis transmembrane conductance regulator (CFTR) gene and a sodium channel epithelial 1 alpha (SCNN1A) gene, comprising a Cas9 molecule, and a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, and cells comprising such genome editing systems and compositions. Also provided are methods for using the genome editing systems, compositions, and cells for genome engineering (e.g., altering a CFTR gene and/or a SCNN1A gene), and for preventing or treating Cystic Fibrosis (CF) and CF-like disease.

CRISPR/CAS-related methods and compositions for treating cystic fibrosis

CRISPR/Cas-related methods and compositions for treating herpes simplex virus

The present invention provides engineered bacteriophages that express at least one biofilm degrading enzyme on their surface and uses thereof for degrading bacterial biofilms. The invention also provides genetically engineered bacteriophages expressing the biofilm degrading enzymes and proteins necessary for the phage to replicate in different naturally occurring biofilm producing bacteria. The phages of the invention allow a method of biofilm degradation by the use of one or only a few administration of the phage because the system using these phages is self perpetuating, and capable of degrading biofilm even when the concentration of bacteria within the biofilm is low.

Engineered enzymatically active bacteriophages and methods of uses thereof

Growing community of inventors

Boston, MA, United States of America

Ari E Friedland